Charles McWherter - Jan 19, 2024 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
President of R&D
Signature
/s/ Paul Quinlan, as attorney-in-fact for Charles McWherter
Stock symbol
CBAY
Transactions as of
Jan 19, 2024
Transactions value $
-$305,123
Form type
4
Date filed
1/22/2024, 06:59 PM
Previous filing
Dec 18, 2023
Next filing
Jan 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $2.39K +2.25K +15% $1.06* 17.3K Jan 19, 2024 Direct
transaction CBAY Common Stock Sale -$53.3K -2.25K -13.04% $23.67 15K Jan 19, 2024 Direct F1, F2
transaction CBAY Common Stock Options Exercise $4.78K +2.78K +18.52% $1.72* 17.8K Jan 19, 2024 Direct
transaction CBAY Common Stock Sale -$65.7K -2.78K -15.63% $23.66 15K Jan 19, 2024 Direct F1, F2
transaction CBAY Common Stock Options Exercise $3.49K +1.92K +12.77% $1.82* 16.9K Jan 19, 2024 Direct
transaction CBAY Common Stock Sale -$45.3K -1.92K -11.33% $23.66 15K Jan 19, 2024 Direct F1, F2
transaction CBAY Common Stock Options Exercise $83.3K +8.33K +55.56% $10.00 23.3K Jan 19, 2024 Direct
transaction CBAY Common Stock Sale -$197K -8.33K -35.72% $23.68 15K Jan 19, 2024 Direct F1, F3
transaction CBAY Common Stock Options Exercise $36.5K +3.13K +20.83% $11.69 18.1K Jan 19, 2024 Direct
transaction CBAY Common Stock Sale -$74K -3.13K -17.24% $23.68 15K Jan 19, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -2.25K -4.17% $0.00 51.8K Jan 19, 2024 Common Stock 2.25K $1.06 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -2.78K -2.78% $0.00 97.2K Jan 19, 2024 Common Stock 2.78K $1.72 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -1.92K -4.17% $0.00 44.1K Jan 19, 2024 Common Stock 1.92K $1.82 Direct F5
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -8.33K -8.33% $0.00 91.7K Jan 19, 2024 Common Stock 8.33K $10.00 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -3.13K -2.08% $0.00 147K Jan 19, 2024 Common Stock 3.13K $11.69 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 29, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $24.20, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.305, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option vested as to 1/4 of the underlying shares on the first anniversary of the grant date and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
F5 The option vested as to 1/2 of the underlying shares on December 30, 2016 and the remaining 1/2 of the underlying shares vested on January 4, 2017.
F6 The option vested as to 1/4 of the underlying shares on January 1, 2019 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.